# TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT05441956** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shenzhen TargetRx Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TGRX-326

## Key facts

- **NCT ID:** NCT05441956
- **Lead sponsor:** Shenzhen TargetRx Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-23
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05441956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05441956, "TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05441956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*